8.97
price up icon5.04%   0.43
after-market 시간 외 거래: 8.97
loading

Regenxbio Inc 주식(RGNX)의 최신 뉴스

pulisher
May 27, 2025

REGENXBIO announces royalty monetization agreement for up to $250M - MSN

May 27, 2025
pulisher
May 26, 2025

REGENXBIO’s SWOT analysis: gene therapy firm’s stock poised for growth - Investing.com Australia

May 26, 2025
pulisher
May 26, 2025

REGENXBIO’s SWOT analysis: gene therapy firm’s stock poised for growth By Investing.com - Investing.com South Africa

May 26, 2025
pulisher
May 21, 2025

REGENXBIO’s $250 Million Royalty Bond Agreement with HealthCare Royalty - Global Legal Chronicle

May 21, 2025
pulisher
May 21, 2025

Coave Therapeutics Establishes New Scientific Advisory Board to Accelerate Innovation in Genetic Medicines for Eye and CNS Diseases - GlobeNewswire Inc.

May 21, 2025
pulisher
May 20, 2025

Regenxbio at RBC Conference: Strategic Moves and Clinical Progress - Investing.com Australia

May 20, 2025
pulisher
May 20, 2025

Regenxbio at RBC Conference: Strategic Moves and Clinical Progress By Investing.com - Investing.com Nigeria

May 20, 2025
pulisher
May 20, 2025

REGENXBIO Announces Strategic Royalty Monetization Agreement for Up to $250 Million | RGNX Stock News - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Stifel maintains Buy on Regenxbio, price target at $40 By Investing.com - Investing.com Nigeria

May 20, 2025
pulisher
May 20, 2025

Stifel maintains Buy on Regenxbio, price target at $40 - Investing.com

May 20, 2025
pulisher
May 20, 2025

Regenxbio Secures $250 Million In New Royalty Bonds - Finimize

May 20, 2025
pulisher
May 19, 2025

REGENXBIO secures $150 million to extend cash runway By Investing.com - Investing.com South Africa

May 19, 2025
pulisher
May 19, 2025

Regenxbio (RGNX) Secures $250M Royalty Bond Deal for Non-Dilutiv - GuruFocus

May 19, 2025
pulisher
May 19, 2025

REGENXBIO (RGNX) Secures $250 Million Non-Dilutive Funding - GuruFocus

May 19, 2025
pulisher
May 19, 2025

REGENXBIO secures $150 million to extend cash runway - Investing.com Australia

May 19, 2025
pulisher
May 19, 2025

RegenXBio Secures $250M Royalty Monetization Deal - TipRanks

May 19, 2025
pulisher
May 19, 2025

REGENXBIO Announces Strategic Royalty Monetization Agreement for Up to $250 Million - Eagle-Tribune

May 19, 2025
pulisher
May 19, 2025

Regenxbio Announces Strategic Royalty Monetization Agreement For Up To $250 Million - marketscreener.com

May 19, 2025
pulisher
May 19, 2025

REGENXBIO's $250M Royalty Deal Extends Cash Runway to 2027, Funds Multiple Late-Stage Programs - Stock Titan

May 19, 2025
pulisher
May 16, 2025

Regenxbio signals RGX-202 pivotal enrollment surpasses 50% as company initiates commercial manufacturing in Q3 2025 - MSN

May 16, 2025
pulisher
May 15, 2025

REGENXBIO’s Earnings Call Highlights Strong Start to Fiscal Year - TipRanks

May 15, 2025
pulisher
May 15, 2025

REGENXBIO’s BLA for MPS II Gene Therapy RGX-121 Accepted for Priority Review by the FDA - CGTLive®

May 15, 2025
pulisher
May 15, 2025

REGENXBIO Inc. Just Missed EPS By 64%: Here's What Analysts Think Will Happen Next - simplywall.st

May 15, 2025
pulisher
May 14, 2025

Regenxbio BLA for Hunter syndrome candidate accepted by FDA - MSN

May 14, 2025
pulisher
May 14, 2025

(RGNX) Proactive Strategies - news.stocktradersdaily.com

May 14, 2025
pulisher
May 14, 2025

Earnings Miss: REGENXBIO Inc. Missed EPS By 64% And Analysts Are Revising Their Forecasts - Yahoo Finance

May 14, 2025
pulisher
May 14, 2025

REGENXBIO Inc. (NASDAQ:RGNX) Q1 2025 Earnings Call Transcript - Insider Monkey

May 14, 2025
pulisher
May 14, 2025

FDA Grants Priority Review to REGENXBIO's (RGNX) Gene Therapy fo - GuruFocus

May 14, 2025
pulisher
May 14, 2025

FDA Accepts Biologics License Application For Mucopolysaccharidosis II Treatment - marketscreener.com

May 14, 2025
pulisher
May 14, 2025

FDA Grants Priority Review to REGENXBIO's (RGNX) Gene Therapy for MPS II | RGNX Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

FDA Accepts Biologics License Application for Mucopolysaccharidosis II Treatment - Eastern Progress

May 14, 2025
pulisher
May 14, 2025

US FDA accepts Regenxbio’s application for MPS II gene therapy - World Pharmaceutical Frontiers

May 14, 2025
pulisher
May 14, 2025

Earnings call transcript: Regenxbio Q1 2025 misses forecasts, stock rises By Investing.com - Investing.com Nigeria

May 14, 2025
pulisher
May 14, 2025

Stifel maintains buy on Regenxbio, reiterates $40 target - Investing.com Australia

May 14, 2025
pulisher
May 14, 2025

Regenxbio (RGNX) Gains FDA Priority Review for RGX-121 BLA | RGN - GuruFocus

May 14, 2025
pulisher
May 13, 2025

Transcript : REGENXBIO Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 05 - marketscreener.com

May 13, 2025
pulisher
May 13, 2025

Stifel maintains buy on Regenxbio, reiterates $40 target By Investing.com - Investing.com India

May 13, 2025
pulisher
May 13, 2025

REGENXBIO (RGNX) Reports Decrease in Q1 Revenue, Focuses on Gene Therapy Progress | RGNX Stock News - GuruFocus

May 13, 2025
pulisher
May 13, 2025

REGENXBIO Reports First Quarter 2025 Financial Results and Recen - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Regenxbio Says Potential Hunter Syndrome Treatment Granted FDA Priority Review - marketscreener.com

May 13, 2025
pulisher
May 13, 2025

Regenxbio stock rises on FDA’s priority review for MPS II therapy - Investing.com Nigeria

May 13, 2025
pulisher
May 13, 2025

Regenxbio stock rises on FDA’s priority review for MPS II therapy By Investing.com - Investing.com South Africa

May 13, 2025
pulisher
May 13, 2025

Regenxbio Announces FDA Acceptance And Priority Review Of BLA For Rgx-121 For Mps Ii - marketscreener.com

May 13, 2025
pulisher
May 13, 2025

REGENXBIO Announces FDA Acceptance and Priority Review of the BL - GuruFocus

May 13, 2025
$1.06
price up icon 0.95%
$31.31
price up icon 3.40%
$580.95
price up icon 0.82%
$292.90
price up icon 2.57%
$4.64
price up icon 6.67%
$77.49
price up icon 4.82%
자본화:     |  볼륨(24시간):